Northern Trust Corp Chinook Therapeutics, Inc. Transaction History

Northern Trust Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$18.66 - $38.58 $1.02 Million - $2.1 Million	54,472 Added 10.22%	587,576 $22.6 Million
Q1 2023 May 15, 2023	SELL	$21.53 - $26.8 $15,243 - $18,974	-708 Reduced 0.13%	533,104 $12.3 Million
Q4 2022 Feb 13, 2023	BUY	$18.63 - $27.35 $2.08 Million - $3.06 Million	111,777 Added 26.49%	533,812 $14 Million
Q3 2022 Nov 14, 2022	BUY	$17.51 - $23.37 $587,075 - $783,549	33,528 Added 8.63%	422,035 $8.3 Million
Q2 2022 Aug 12, 2022	BUY	$12.59 - $18.8 $481,152 - $718,479	38,217 Added 10.91%	388,507 $6.8 Million
Q1 2022 May 13, 2022	BUY	$12.02 - $16.69 $25,398 - $35,265	2,113 Added 0.61%	350,290 $5.73 Million
Q4 2021 Feb 08, 2022	BUY	$10.69 - $16.83 $473,983 - $746,225	44,339 Added 14.59%	348,177 $5.68 Million
Q3 2021 Nov 15, 2021	SELL	$11.5 - $14.86 $30,452 - $39,349	-2,648 Reduced 0.86%	303,838 $3.88 Million
Q2 2021 Aug 13, 2021	BUY	$13.6 - $18.98 $1.61 Million - $2.24 Million	118,249 Added 62.82%	306,486 $4.33 Million
Q1 2021 May 12, 2021	SELL	$14.17 - $19.11 $152,426 - $205,566	-10,757 Reduced 5.41%	188,237 $2.93 Million
Q4 2020 Feb 11, 2021	BUY	$11.9 - $20.91 $2.37 Million - $4.16 Million	198,994 New	198,994 $3.16 Million

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

Stay updated on Northern Trust Corp with notifications on news.